CellCentric

Executive Summary

CellCentric is a clinical-stage biopharmaceutical company pioneering first-in-class oral small molecule inhibitors of p300/CBP, transcription co-activators implicated in cancer. Based in Cambridge, UK, its lead asset, inobrodib, is being developed for multiple myeloma and other hematologic malignancies. By targeting the epigenetic machinery that drives oncogenic gene expression, inobrodib offers a novel mechanism distinct from standard therapies, with the potential for convenient oral dosing. The company's mission is to reduce treatment burden while improving outcomes, addressing significant unmet need in relapsed/refractory multiple myeloma where patients often cycle through multiple lines of therapy. CellCentric's clinical program is in Phase 1, with initial data expected to demonstrate safety, tolerability, and early efficacy signals. The company is well-positioned to advance inobrodib into later-stage trials, potentially as a combination agent with existing multiple myeloma treatments. As a private entity, CellCentric may seek additional financing or partnerships to support development. Key upcoming catalysts include the release of dose-escalation data, updates on expansion cohorts, and progress toward a Phase 2 registration strategy. With a focus on a validated yet underexploited target, CellCentric represents a high-risk, high-reward opportunity in the oncology space.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 dose-escalation data for inobrodib in multiple myeloma60% success
• Q1 2027Initiation of Phase 2 expansion cohorts in multiple myeloma and other indications50% success
• TBDPartnership or licensing deal for inobrodib in non-oncology indications20% success